Thomas C. Wascher, Bernhard Paulweber, Hermann Toplak, C H Saely, Heinz Drexel, Bernhard Föger, Friedrich Hoppichler, Thomas Stulnig, Harald Stingl, Florian Höllerl, Martin Clodi
Hyperlipidemia and dyslipidemia make a substantial contribution to cardiovascular morbidity and mortality in people with diabetes mellitus. Pharmacotherapy with statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and bempedoic acid has convincingly been shown to reduce the cardiovascular risk of people with diabetes. The present article presents the treatment recommendations of the Austrian Diabetes Association for the use of lipid-lowering drugs in people with diabetes according to current scientific evidence.